<p class="title">Biotechnology firm Biocon said its partner Mylan has re-submitted marketing authorisation applications with the European drug regulator European Medicines Agency for two biosimilars Trastuzumab and Pegfilgrastim, reports PTI from New Delhi.</p>
<p class="title">Biotechnology firm Biocon said its partner Mylan has re-submitted marketing authorisation applications with the European drug regulator European Medicines Agency for two biosimilars Trastuzumab and Pegfilgrastim, reports PTI from New Delhi.</p>
